Physician profile
Eric Lange
NPI 1063973493
$9,209.42
in general payments reported to CMS, 2019-2025
19 companies · $3,022 in 2025
The $3,022 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.24 · 2023: $2,456 · 2024: $3,720 · 2025: $3,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,197.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,967.71 | 2023-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $1,524.46 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,190.55 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,010.71 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $764.35 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $536.50 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $354.08 | 2023-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $300.90 | 2023-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $252.66 | 2023-2025 | Trintellix |
| Tris Pharma INC | $216.56 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Idorsia Pharmaceuticals US INC | $213.58 | 2023-2025 | Quviviq, Quviviq |
| Lundbeck LLC | $188.76 | 2023-2025 | Rexulti |
| Corium, LLC | $183.08 | 2023-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $165.12 | 2023-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $102.94 | 2023-2025 | Adzenys Xr-Odt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $101.88 | 2023-2024 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $94.36 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $28.98 | 2025 | Austedo Xr |
| Genentech USA, INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.